New Weight-Loss Drugs Rival Wegovy in Large-Scale Trials

Recent studies show promising developments in weight loss drugs, with multiple new options demonstrating significant efficacy. China's Sciwind Biosciences' experimental drug ecnoglutide, a GLP-1 receptor agonist, led to an average weight loss of 10% to 15%, comparable to Novo Nordisk's Wegovy, and could increase market competition and accessibility. Novo Nordisk is also advancing with a higher dose of Wegovy (semaglutide 7.2 mg), which produced an average 21% weight loss in people with obesity, offering a new option for patients who need greater weight reduction. Meanwhile, Novo Nordisk's amycretin, targeting GLP-1 and amylin receptors, showed potential for weight loss exceeding Wegovy, with injectable forms achieving nearly 24% body weight loss and an oral tablet form causing over 13% loss, which could simplify treatment delivery and expand NHS access. Side effects across these drugs are generally similar, including nausea and gastrointestinal symptoms, but are mostly manageable. These advancements highlight a growing landscape of weight loss therapies that may improve both effectiveness and accessibility for patients worldwide.